Figures and Tables

From the following article:

BCL-2 family antagonists for cancer therapy

Guillaume Lessene, Peter E. Czabotar & Peter M. Colman

Nature Reviews Drug Discovery 7, 989-1000 (December 2008)

doi:10.1038/nrd2658

Figure 1 - BCL-2 family antagonists for cancer therapy

Figure 1

The extended BCL-2 protein family.

Figure 2 - BCL-2 family antagonists for cancer therapy

Figure 2

Structures of pro-survival proteins with BH3 ligands.

Figure 3 - BCL-2 family antagonists for cancer therapy

Figure 3

Interactions between proteins of the extended BCL-2 family determine the integrity of the outer mitochondrial membrane.

Figure 4 - BCL-2 family antagonists for cancer therapy

Figure 4

BH3 domain sequences of BH3-only proteins and their pro-survival protein binding targets.

Figure 5 - BCL-2 family antagonists for cancer therapy

Figure 5

Interactions between pro-survival BCL-2 proteins and BH3 ligands as exemplified by the MCL1–BIM BH3 complex.

Figure 6 - BCL-2 family antagonists for cancer therapy

Figure 6

Structural studies related to the discovery of ABT-737.

Table 1 - BCL-2 family antagonists for cancer therapy

Table 1

Putative BCL-2 inhibitors